- Previous Close
46.60 - Open
46.65 - Bid 45.50 x --
- Ask 45.80 x --
- Day's Range
45.65 - 46.70 - 52 Week Range
35.15 - 80.90 - Volume
16,370 - Avg. Volume
59,777 - Market Cap (intraday)
3.266B - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-2.11 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company's products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States. The company was founded in 2014 and is based in Taipei City, Taiwan.
www.sinewpharma.comRecent News: 6634.TWO
View MorePerformance Overview: 6634.TWO
Trailing total returns as of 4/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6634.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6634.TWO
View MoreValuation Measures
Market Cap
3.32B
Enterprise Value
2.17B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
2.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-8.15%
Return on Equity (ttm)
-11.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-150.37M
Diluted EPS (ttm)
-2.11
Balance Sheet and Cash Flow
Total Cash (mrq)
1.16B
Total Debt/Equity (mrq)
0.24%
Levered Free Cash Flow (ttm)
-63.29M